Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
|Articles|September 26, 2012
Deficit Continues To Be Test For Obama -- With Debate About Medicare And Medicaid Central To Both Campaigns
Advertisement
The New York Times reports that with the deficit over $1 trillion, President Barack Obama and GOP presidential pick Mitt Romney propose different prescriptions, especially regarding government health programs. Meanwhile, the Wall Street Journal reports on how health firms are preparing for possible election outcomes.
Read the full story:
For the New York Times story
Source: Kaiser Health News/The New York Times
Advertisement
Related to this article
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
5